Neurodegenerative Disease Mechanisms and Therapeutic Interventions

Neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis arise from progressive dysfunction and loss of neurons driven by multifactorial mechanisms. Central to this process is the misfolding and aggregation of key proteins—amyloid-β and tau in Alzheimer’s, α-synuclein in Parkinson’s, and TDP-43 in amyotrophic lateral sclerosis—leading to synaptic loss, axonal transport deficits and neuronal death. These aggregates often trigger aberrant activation of microglia and astrocytes, instigating a chronic neuroinflammatory state driven by pro-inflammatory cytokines and oxidative stress. Genetic and environmental factors intersect to modulate disease onset and progression, with mutations in APP, PSEN1/2 or SNCA genes, and risk loci such as APOE, influencing protein handling. Emerging therapeutic interventions aim to target these mechanisms at multiple levels: immunotherapy directed against pathogenic proteins, small molecules to inhibit aggregation or restore proteostasis, modulation of neuroinflammatory pathways, and gene-editing strategies to correct causal mutations. Advances in biomarker discovery, including blood-based assays for protein fragments or metabolite profiles, promise earlier diagnosis and stratification of at-risk individuals, enabling interventions at preclinical stages. Together, these insights underpin a shift towards precision medicine approaches that combine mechanistic modulation with early detection to modify disease trajectories and improve patient outcomes.

Research from Nature Portfolio

Recent studies have highlighted the therapeutic potential of targeting peripheral factors that exacerbate central pathology. One investigation demonstrated that antibody-based inhibition of circulating acid sphingomyelinase attenuates the differentiation of pathogenic Th17 cells and reduces amyloid-β deposition in a mouse model, offering a novel immunotherapeutic strategy that bridges systemic and central inflammatory responses. This work underscores the importance of blood-brain barrier-permeable targets and the interplay between peripheral immune modulation and neurodegenerative processes.

Neurodegenerative Disease Mechanisms and Therapeutic Interventions publication trend

The graph below shows the total number of articles in neurodegenerative disease mechanisms and therapeutic interventions across all publications each year (not limited to Nature Index journals).

Technical terms

Amyloid-β (Aβ): peptide prone to misfold and form extracellular plaques in Alzheimer’s disease.

Tau fibrils: intraneuronal aggregates of hyperphosphorylated tau protein characteristic of tauopathies.

Microglia: resident immune cells of the central nervous system involved in inflammation and clearance of debris.

Neuroinflammation: chronic activation of central immune pathways that can exacerbate neuronal damage.

Reactive oxygen species (ROS): highly reactive molecules that contribute to oxidative stress and cellular injury.

Immunotherapy: treatment approach that uses antibodies or immune modulators to target pathogenic proteins.

Acid sphingomyelinase (ASM): enzyme involved in sphingolipid metabolism, implicated in peripheral modulation of neurodegenerative pathology.

Organoids: three-dimensional tissue cultures derived from stem cells that model organ structure and function in vitro.

References

1. Immunotherapy targeting plasma ASM is protective in a mouse model of Alzheimer’s disease. Nature Communications (2023).
2. Circulating arginine metabolites in Alzheimer’s disease and vascular dementia: A systematic review and meta-analysis. Ageing Research Reviews (2023).
3. Cerebral organoids with chromosome 21 trisomy secrete Alzheimer’s disease-related soluble aggregates detectable by single-molecule-fluorescence and super-resolution microscopy. Molecular Psychiatry (2023).
4. ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease. Antioxidants (2020).